Results 41 to 50 of about 45,696 (262)

DataSheet1_Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis.docx

, 2021
Objective: To systematically review and compare the efficacy and posttreatment resistance of ceftazidime-avibactam therapy and ceftazidime-avibactam-based combination therapy in patients with Gram-negative pathogens.Methods: PubMed, Embase, Web of ...
Xiangning Huang (5216384), Shanshan Long (1783180), Hao Zhou (136535), Jie Zhang (64655), Dan Li (106345), Fan Fei (1368924), Hua Yu (138267)   +6 more
core   +1 more source

In Vitro and In Vivo Evaluations of β-Lactam/β-Lactamase Mono- and Combined Therapies against Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan

Microorganisms, 2020
Increasing carbapenem resistance rates worldwide underscored the urgent need of novel antimicrobials. Ceftazidime–avibactam and aztreonam–avibactam combinations are developed to combat carbapenem resistance, but biological and geographic variations must ...
Tsung-Ying Yang, Ya-Ju Hsieh, Li-Ting Kao, Guan-Hong Liu, Shao-Hsuan Lian, Liang-Chun Wang, I-Ling Lin, Yu-Tzu Lin, Sheng-Fan Wang, Sung-Pin Tseng, Po-Liang Lu   +10 more
doaj   +1 more source

Table1_Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis.docx

, 2021
Objective: To systematically review and compare the efficacy and posttreatment resistance of ceftazidime-avibactam therapy and ceftazidime-avibactam-based combination therapy in patients with Gram-negative pathogens.Methods: PubMed, Embase, Web of ...
Xiangning Huang (5216384), Shanshan Long (1783180), Hao Zhou (136535), Jie Zhang (64655), Dan Li (106345), Fan Fei (1368924), Hua Yu (138267)   +6 more
core   +1 more source

Analysis of the clinical application of ceftazidime-avibactam in China

Journal of Infection and Public Health, 2022
The efficacy and safety of ceftazidime-avibactam were mainly reported in phase II and phase III clinical trials, rarely in the real-world study. The limited real-world study which evaluated the clinical response of this drug shown inconsistent results.
Qing Wang, Ping Xu, Yangang Zhou
openaire   +3 more sources

Data_Sheet_1_Identification of a Novel Ceftazidime-Avibactam-Resistant KPC-2 Variant, KPC-123, in Citrobacter koseri Following Ceftazidime-Avibactam Treatment.PDF

, 2022
This study reported the identification of a novel ceftazidime-avibactam-resistant KPC-2 variant, KPC-123, in a Citrobacter koseri isolated from a patient in a Chinese hospital following ceftazidime-avibactam treatment of infection caused by OXA-232 ...
Weiyi Shen (1835500), Rong Zhang (44942), Jiachang Cai (10146251), Lin Wang (11986)   +3 more
core   +1 more source

Acetylcysteine increases sensitivity of ceftazidime-avibactam–resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo

BMC Microbiology, 2023
Abstract Background Ceftazidime-avibactam (CZA) improves treatment outcomes for infections caused by carbapenem-resistant organisms, but has led to serious bacterial resistance. Acetylcysteine (NAC) is an approved medication that protects the respiratory tract through antioxidant and anti-inflammatory effects.
Zeyu Huang, Yijia Han, Xiaotuan Zhang, Yao Sun, Yuzhan Lin, Luozhu Feng, Tieli Zhou, Zhongyong Wang   +7 more
openaire   +3 more sources

Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing

Antibiotics, 2022
Multidrug resistance (MDR) represents a serious global threat due to the rapid global spread and limited antimicrobial options for treatment of difficult-to-treat (DTR) infections sustained by MDR pathogens.
P. Gaibani, Tommaso Giani, Federica Bovo, D. Lombardo, Stefano Amadesi, T. Lazzarotto, M. Coppi, G. Rossolini, S. Ambretti   +8 more
semanticscholar   +1 more source

Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales

Antibiotics, 2020
Background: Experience in real clinical practice with ceftazidime-avibactam for the treatment of serious infections due to gram−negative bacteria (GNB) other than carbapenem-resistant Enterobacterales (CRE) is very limited.
Antonio Vena, Daniele Roberto Giacobbe, Nadia Castaldo, Annamaria Cattelan, Cristina Mussini, Roberto Luzzati, Francesco Giuseppe De Rosa, Filippo Del Puente, Claudio Maria Mastroianni, Antonio Cascio, Sergio Carbonara, Alessandro Capone, Silvia Boni, Chiara Sepulcri, Marianna Meschiari, Francesca Raumer, Alessandra Oliva, Silvia Corcione, Matteo Bassetti, for the Ceftabuse Study Group   +19 more
doaj   +1 more source

Resistance to ceftazidime–avibactam and underlying mechanisms

Journal of Global Antimicrobial Resistance, 2020
Ceftazidime-avibactam (CAZ-AVI) is a novel synthetic β-lactamase inhibitor combination. Although the combination has been available clinically for only a few years, cases of resistance to CAZ-AVI have already been reported.In the present review, we summarize the distribution of CAZ-AVI-resistant strains and the possible resistance mechanisms.There are ...
Yuhang Wang, Jin Wang, Rui Wang, Yun Cai
openaire   +3 more sources

Efficacy and mortality of ceftazidime/avibactam-based regimens in carbapenem-resistant Gram-negative bacteria infections: A retrospective multicenter observational study.

Journal of Infection and Public Health, 2023
OBJECTIVES Limited data on clinical and microbiological efficacy, patient mortality, and other associated factors are available for ceftazidime/avibactam (CAZ/AVI)-based regimens for carbapenem-resistant Gram-negative bacteria (CR-GNB).
Haiwen Zhuang, Ying Chen, Qin Hu, Wen Long, Xiao-li Wu, Qin Wang, Tian T Xu, Q. Qu, Yi-Ping Liu, Yi Xiao, J. Qu   +10 more
semanticscholar   +1 more source